查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586190

细胞免疫治疗市场：按类型、按适应症、按技术类型、按最终用途 - 2025-2030 年全球预测

Cellular Immunotherapy Market by Type (CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy), Indication (B-Cell Malignancies, Liver Cancer, Prostate Cancer), Technology Type, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

细胞免疫治疗市场2023年估值为112.3亿美元，预计2024年将达140.2亿美元，复合年增长率为25.34%，预计到2030年将达到546亿美元。

细胞免疫疗法是癌症治疗的前沿领域，它利用人体自身的免疫细胞（例如 T 细胞）来瞄准并摧毁癌细胞。这种方法非常重要，因为它有可能提供高度客製化的治疗方法，并且比传统治疗方法的副作用更少。对未满足关键字的需求在于它们能够解决未满足的医疗需求，特别是对传统治疗方法有抵抗力的癌症。应用主要集中在肿瘤学领域，重点关注白血病和淋巴瘤等骨髓恶性肿瘤，但正在迅速扩展到包括固态肿瘤和慢性感染疾病。最终用途包括医院、癌症研究中心和生技公司。该市场受到癌症发病率上升、基因工程技术进步以及研发投资增加的推动。主要成长要素包括对精准医疗的需求不断增加以及政府对新治疗方法的支持和核准。最近 FDA核准CAR T 细胞疗法证实了巨大的机会，并鼓励相关人员投资 NK 细胞疗法和联合治疗等下一代技术。然而，挑战依然存在，包括复杂的製造流程、高昂的处理成本和监管障碍。也有一些限制，例如潜在的治疗相关毒性以及患者接受治疗之前的较长前置作业时间。创新应着重于提高治疗方法的安全性和有效性、降低製造成本以及增加患者的可近性。开发现成的同种异体移植解决方案和个人化治疗方法的研究可能会产生有意义的进展。市场仍然充满活力，其特点是快速的技术创新和竞争格局，合作和收购频繁地塑造成长轨迹。公司必须透过建立策略伙伴关係并继续适应技术变革来利用这些趋势。透过这样做，您可以克服挑战并在这一重要领域建立强大的投资组合。

主要市场统计
基准年[2023] 112.3亿美元
预测年份 [2024] 140.2亿美元
预测年份 [2030] 546亿美元
复合年增长率（%） 25.34%

市场动态：揭示快速发展的细胞免疫治疗市场的关键市场洞察

供需的动态交互作用正在改变细胞免疫治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 癌症和先进细胞疗法的普及
    • 政府积极致力于细胞疗法的研发
    • 肿瘤浸润淋巴细胞（TIL）疗法和人工T细胞受体（TCR）疗法的扩展
  • 市场限制因素
    • 设备和治疗方法的初始成本较高
  • 市场机会
    • 细胞免疫疗法相关技术进展及新产品
    • 各种细胞免疫疗法药物的核准增加
  • 市场挑战
    • 产品召回和严格的监管核准

波特五力：驾驭细胞免疫治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解细胞免疫治疗市场的外部影响

外部宏观环境因素在塑造细胞免疫治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解细胞免疫治疗市场的竞争格局

对细胞免疫治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵细胞免疫治疗市场供应商绩效评估

FPNV定位矩阵是评估细胞免疫疗法市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了细胞免疫治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，细胞免疫治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症流行和先进的细胞治疗方法
      • 政府对细胞疗法研究和开发的有利方法
      • 肿瘤浸润淋巴细胞 (TIL) 和工程化 T 细胞受体 (TCR) 疗法的普及率不断上升
    • 抑制因素
      • 设备和治疗方法的初始成本很高
    • 机会
      • 细胞免疫疗法的技术进步与新产品
      • 各种基于细胞的免疫疗法药物的核准增加
    • 任务
      • 产品召回和严格的监管核准
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章细胞免疫治疗市场：依类型

  • CAR-T细胞疗法
  • 树突细胞疗法
  • NK细胞疗法
  • 肿瘤浸润淋巴细胞治疗

第七章依适应症分類的细胞免疫治疗市场

  • B细胞恶性
  • 肝癌
  • 摄护腺癌
  • 肾臟细胞癌

第八章按技术类型分類的细胞免疫治疗市场

  • 细胞激素和免疫调节剂
  • 单株抗体

第九章细胞免疫治疗市场：依最终用途分类

  • 癌症研究所
  • 医院

第十章美洲细胞免疫治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区细胞免疫治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲细胞免疫治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Adaptimmune Therapeutics PLC
  • Adicet Bio, Inc.
  • Apac Biotech Private Limited
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Celyad Oncology SA
  • Corning Incorporated
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glycostem Therapeutics BV
  • Immatics NV
  • Inovio Pharmaceuticals, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics（Shanghai）Co., Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Tessa Therapeutics Ltd.
Product Code: MRR-7C50F2739738

The Cellular Immunotherapy Market was valued at USD 11.23 billion in 2023, expected to reach USD 14.02 billion in 2024, and is projected to grow at a CAGR of 25.34%, to USD 54.60 billion by 2030.

Cellular immunotherapy, a pioneering field within cancer treatment, leverages the body's immune cells, such as T-cells, to target and destroy cancerous cells. This approach is critical due to its potential to offer highly tailored therapies with fewer side effects compared to conventional treatments. The necessity of cellular immunotherapy lies in its capacity to address unmet medical needs, particularly for cancers that are resistant to traditional therapies. Applications are primarily in oncology, focusing on hematological malignancies like leukemia and lymphoma, but it's rapidly expanding into solid tumors and chronic infections. End-use encompasses hospitals, cancer research centers, and biotech firms. The market is driven by a rise in cancer prevalence, technological advancements in genetic engineering, and increasing investments in R&D. Key growth factors include governmental support and approval of new therapies, alongside the escalating demand for precision medicine. Recent FDA approvals of CAR T-cell therapies underscore significant opportunities, urging stakeholders to invest in next-gen technologies like NK-cell therapies and combination treatments. However, challenges persist, such as complex manufacturing processes, high treatment costs, and regulatory hurdles. Limitations also include potential therapy-related toxicity and long lead times to patient availability. Innovation should focus on improving the safety and efficacy of therapies, reducing production costs, and enhancing patient accessibility. Research into developing allogeneic, off-the-shelf solutions and personalized treatment regimens could offer meaningful advancements. The market remains dynamic, characterized by rapid innovation and a competitive landscape, with collaborations and acquisitions frequently shaping growth trajectories. Companies must capitalize on these trends by building strategic partnerships and remaining adaptive to technological shifts. By doing so, they can navigate challenges and ensure robust portfolio development in this critical field.

KEY MARKET STATISTICS
Base Year [2023] USD 11.23 billion
Estimated Year [2024] USD 14.02 billion
Forecast Year [2030] USD 54.60 billion
CAGR (%) 25.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cellular Immunotherapy Market

The Cellular Immunotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of cancer and advanced cell based therapies
    • Favorable government initiatives for cellular therapies R&D
    • Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
  • Market Restraints
    • High initial costs of devices and therapies
  • Market Opportunities
    • Technological advancements and new products for cellular immunotherapy
    • Increasing approvals of different cell-based immunotherapy drugs
  • Market Challenges
    • Product recalls and stringent regulatory approvals

Porter's Five Forces: A Strategic Tool for Navigating the Cellular Immunotherapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cellular Immunotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cellular Immunotherapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cellular Immunotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cellular Immunotherapy Market

A detailed market share analysis in the Cellular Immunotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cellular Immunotherapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cellular Immunotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cellular Immunotherapy Market

A strategic analysis of the Cellular Immunotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cellular Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Apac Biotech Private Limited, AstraZeneca PLC, Atara Biotherapeutics, Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Celyad Oncology SA, Corning Incorporated, Dendreon Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glycostem Therapeutics B.V., Immatics N.V., Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., JW Therapeutics (Shanghai) Co., Ltd., Lonza Group Ltd., Merck KGaA, Novartis AG, Pfizer Inc., and Tessa Therapeutics Ltd..

Market Segmentation & Coverage

This research report categorizes the Cellular Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, and Tumor-Infiltrating Lymphocytes Therapy.
  • Based on Indication, market is studied across B-Cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
  • Based on Technology Type, market is studied across Cytokines & Immunomodulators and Monoclonal Antibodies.
  • Based on End-Use, market is studied across Cancer Institutes and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancer and advanced cell based therapies
      • 5.1.1.2. Favorable government initiatives for cellular therapies R&D
      • 5.1.1.3. Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
    • 5.1.2. Restraints
      • 5.1.2.1. High initial costs of devices and therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements and new products for cellular immunotherapy
      • 5.1.3.2. Increasing approvals of different cell-based immunotherapy drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Product recalls and stringent regulatory approvals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cellular Immunotherapy Market, by Type

  • 6.1. Introduction
  • 6.2. CAR T-Cell Therapy
  • 6.3. Dendritic Cell Therapy
  • 6.4. NK Cell Therapy
  • 6.5. Tumor-Infiltrating Lymphocytes Therapy

7. Cellular Immunotherapy Market, by Indication

  • 7.1. Introduction
  • 7.2. B-Cell Malignancies
  • 7.3. Liver Cancer
  • 7.4. Prostate Cancer
  • 7.5. Renal Cell Carcinoma

8. Cellular Immunotherapy Market, by Technology Type

  • 8.1. Introduction
  • 8.2. Cytokines & Immunomodulators
  • 8.3. Monoclonal Antibodies

9. Cellular Immunotherapy Market, by End-Use

  • 9.1. Introduction
  • 9.2. Cancer Institutes
  • 9.3. Hospitals

10. Americas Cellular Immunotherapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cellular Immunotherapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cellular Immunotherapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptimmune Therapeutics PLC
  • 2. Adicet Bio, Inc.
  • 3. Apac Biotech Private Limited
  • 4. AstraZeneca PLC
  • 5. Atara Biotherapeutics, Inc.
  • 6. Bio-Rad Laboratories, Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Celyad Oncology SA
  • 9. Corning Incorporated
  • 10. Dendreon Pharmaceuticals LLC
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche AG
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline PLC
  • 15. Glycostem Therapeutics B.V.
  • 16. Immatics N.V.
  • 17. Inovio Pharmaceuticals, Inc.
  • 18. Iovance Biotherapeutics, Inc.
  • 19. Johnson & Johnson Services, Inc.
  • 20. JW Therapeutics (Shanghai) Co., Ltd.
  • 21. Lonza Group Ltd.
  • 22. Merck KGaA
  • 23. Novartis AG
  • 24. Pfizer Inc.
  • 25. Tessa Therapeutics Ltd.

LIST OF FIGURES

  • FIGURE 1. CELLULAR IMMUNOTHERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CELLULAR IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELLULAR IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELLULAR IMMUNOTHERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023